CQDM funds the development of a novel artificial intelligence tool for cardiovascular clinical trials
Home > Press room > CQDM funds the development of a novel artificial intelligence tool for cardiovascular clinical trials
Copied link!
Share
November 5, 2020
─
A collaboration between Perceiv AI, DalCor Pharmaceuticals and the Montreal Heart Institute
The CQDM is pleased to announce the launch of a $600,000 collaborative project in biopharma and artificial intelligence (AI) to develop an AI-driven precision medicine tool.
the project supports the development of AI-driven digital biomarkers to identify patients who would specifically benefit from given medicines being tested in cardiovascular disease clinical trials.
find out more by visiting the Institute’s websitePress Room
December 6, 2023The Right Honourable Brian Mulroney and Mrs. Mila Mulroney donate $1.5 million to support the foundations of two hospitals and a research institute
October 31, 2023Céline Auger, Dominique Morency-Laflamme, and Isabelle Gauthier named recipients of the 2023 Dr. Denis Roy Awards for Excellence in Cardiovascular Care
September 8, 202323rd edition of the Grand Bal des Vins-Cœurs: $1,380,000 raised for the Montreal Heart Institute Foundation